Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health have removed a major roadblock to better understanding of mpox (formerly, monkeypox). They developed a mouse model of the disease and used…
A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses…
A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy…
An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined. The HPX3002/HVTN 706,…
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.…
Bacterial infectious diseases are still a huge contributor to global disease burden and with antibiotic resistance on the rise worldwide there is an urgent need for novel treatment strategies against bacteria. One of the most devastating bacterial infections is Cholera,…
A clinical trial to evaluate the antiviral drug tecovirimat, also known as TPOXX, in adults and children with monkeypox has begun in the Democratic Republic of the Congo (DRC). The trial will evaluate the drug’s safety and its ability to…
Findings from a small study of eight patients published in Clinical Infectious Diseases suggest that COVID-19 rebound is likely not caused by impaired immune responses. The study, led by scientists at the National Institute of Allergy and Infectious Diseases (NIAID),…
UW Medicine researchers are recruiting participants for a Phase 3 clinical trial of a drug to treat the monkeypox virus. The drug, tecovirimat, is approved by the U.S. Food and Drug Administration to treat smallpox. Investigators hope this study will…
